位置:首页 > 产品库 > Tubercidin
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Tubercidin
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Tubercidin图片
CAS NO:69-33-0
包装与价格:
包装价格(元)
5 mg询价
10 mg询价
25 mg询价
50 mg询价
100 mg询价
1 mL*10 mM(in DMSO)询价

杀结核菌素
Sparsomycin A
结核菌素
7-Deazaadenosine
Tubercidin是从Streptomyces tubercidicus得到的抗生素,抑制粪链球菌生长的IC50值为 0.02 μM。它是腺苷磷酸化酶的弱抑制剂,并干扰腺苷和 AMP 的磷酸化。它有抗病毒作用。

产品描述

Tubercidin, an adenosine analogue, is a nucleoside antibiotic. It is incorporated into DNA and inhibits polymerases, thereby inhibiting DNA replication and RNA and protein synthesis. This agent also exhibits antifungal and antiviral activities.

体外活性

Continuous exposure for 14 days to tubercidin alone is highly toxic to both human CFU-GM and BFU-E. The IC50s of tubercidin are 3.4±1.7 and 3.7±0.2 nM for CFU-GM and BFU-E, respectively. Tubercidin also has a direct dose-dependent inhibitory effect on myeloid and erythroid human bone marrow progenitor cells in vitro[1].

体内活性

Tubercidin at the dose regimen (5 mg/kg everyday for 4 days) is lethal when used alone. Some of the studies show that the mortality from tubercidin is primarily due to hepatic and renal injuries and, to a lesser extent, damage to the pancreas. Coadministration of NBMPR-P at 25 mg/kg per day completely protects the mice (100% survival) from this lethal dose regimen of tubercidin[1].

细胞实验

Human bone marrow cells were obtained from healthy volunteers. In the protection studies, cells are exposed to 10 nM of tubercidin in the presence or absence of various doses of NBMPR-P. Cells are continuously exposed to drugs for 14 days in a humidified atmosphere of 5% C02-95% air at 37°C. Colonies of CFU-GM (250 cells) and BFU-E (>30 hemoglobinized cells) are counted with an inverted microscope. (Only for Reference)

Cas No.

69-33-0

分子式

C11H14N4O4

分子量

266.25

别名

杀结核菌素;Sparsomycin A;结核菌素;7-Deazaadenosine

储存和溶解度

H2O:<1 mgml
DMSO:49 mg/mL (184 mM)
Ethanol:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024